Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

0.7591 -0.0009 (-0.12%)

Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cognition Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

August 22, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q2 2024 ↗

August 08, 2024

CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

August 08, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

August 05, 2024

- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 -

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

July 30, 2024

Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning!

Via InvestorPlace

Dow Edges Lower; Ventyx Biosciences Shares Plummet ↗

July 29, 2024

Via Benzinga

Topics Stocks

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 29, 2024

Via Benzinga

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump ↗

July 29, 2024

Via Benzinga

Tivic Health Systems (TIVC) Stock Pops Another 39% ↗

July 29, 2024

Tivic Health Systems stock is up on Monday with heavy trading of TIVC shares as recent volatility continues for the company's units.

Via InvestorPlace

Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study ↗

July 29, 2024

Cognition Therapeutics' Phase 2 'SHINE' study shows CT1812 leads to cognitive improvement in Alzheimer's patients over six months. Participants showed better performance on cognitive and functional...

Via Benzinga

Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today? ↗

July 29, 2024

NLS Pharmaceutics stock is up on Monday after the company provided NLSP investors with details on a merger deal with Kadimastem.

Via InvestorPlace

Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today? ↗

July 29, 2024

Cognition Therapeutics stock is down on Monday after CGTX investors read the latest data from a Phase 2 clinical trial report.

Via InvestorPlace

Nasdaq Gains 1%; McDonald's Posts Downbeat Results ↗

July 29, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

July 29, 2024

Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!

Via InvestorPlace

Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

July 29, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗

July 29, 2024

Via Benzinga

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024

July 26, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC

July 02, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 22, 2024

Via Benzinga

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

May 21, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024 ↗

May 07, 2024

CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

May 07, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

April 29, 2024

- Top-line Results Expected in the Second Half of 2024 -

From Cognition Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 22, 2024

Via Benzinga

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

April 22, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

April 02, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024

April 01, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023 ↗

March 26, 2024

CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

March 26, 2024

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For March 26, 2024 ↗

March 26, 2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.